<DOC>
	<DOCNO>NCT02404220</DOCNO>
	<brief_summary>This study evaluate safety , efficacy , tolerability , pharmacokinetics entospletinib ( GS-9973 ) combination vincristine ( VCR ) , dexamethasone adult previously treat relapsed refractory B-cell lineage acute lymphoid leukemia ( ALL ) . This study consist two part : Dose Escalation Dose Expansion . After 2 induction cycle either part study , participant may put maintenance 36 cycle obtain clinical benefit treatment .</brief_summary>
	<brief_title>Safety Efficacy Entospletinib With Vincristine Dexamethasone Adults With Relapsed Refractory Acute Lymphoid Leukemia ( ALL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Key Adults ALL need treatment Key Diagnosis Burkitt 's Leukemia , lymphoid blast crisis chronic myelogenous leukemia ( CML ) History myelodysplastic syndrome solid organ transplantation Prior allogeneic bone marrow progenitor cell transplant within 100 day active immunosuppression graft versus host disease ( GVHD ) treatment prophylaxis within 28 day prior enrollment NOTE : Other protocol define Inclusion/ Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Syk inhibitor</keyword>
	<keyword>Blood malignancy</keyword>
	<keyword>Leukemia</keyword>
</DOC>